Annals of Biomedical Engineering

, Volume 44, Issue 6, pp 1970–1982 | Cite as

Design of pH-Responsive Biomaterials to Enable the Oral Route of Hematological Factor IX

Emerging Trends in Biomaterials Research

Abstract

The oral administration of hematological factor IX (FIX) can offer a convenient prophylactic treatment for hemophilia B patients. pH-Responsive hydrogels based on poly(methacrylic acid)-grafted-poly(ethylene glycol) (P(MAA-g-EG)) have been engineered as delivery vehicles for FIX. In oral delivery, such hydrogel carriers protected FIX from the gastric environment and released it under intestinal conditions as demonstrated by evaluation of the loading and release of FIX. Tailoring of the hydrogel networks improved the loading of FIX within the microcarriers, which is critical for minimizing protein degradation. Optimizing the loading conditions by increasing the incubation time and using a reduced ionic strength buffer further improved the delivery potential of the microcarriers. The presence of the microcarriers significantly enhanced the oral absorption of FIX in vitro. As shown in this work, P(MAA-g-EG) microcarriers are promising candidates for the oral delivery of FIX.

Keywords

Biomaterials Drug delivery Hydrogels Factor IX 

Abbreviations

FaSSGF

Fasted-state simulated gastric fluid

FaSSIF

Fasted-state simulated intestinal fluid

hFIX

Human factor IX

MAA

Methacrylic acid

PEGDMA

Poly(ethylene glycol) dimethacrylate

P(MAA-g-EG)

Poly(methacrylic acid)-grafted-poly(ethylene glycol)

Supplementary material

10439_2016_1566_MOESM1_ESM.tif (164 kb)
Supplementary material 1 (TIFF 163 kb)
10439_2016_1566_MOESM2_ESM.tif (4.6 mb)
Supplementary material 2 (TIFF 4729 kb)
10439_2016_1566_MOESM3_ESM.tif (91 kb)
Supplementary material 3 (TIFF 91 kb)

References

  1. 1.
    Brannon-Peppas, L., and N. A. Peppas. Equilibrium swelling behavior of dilute ionic hydrogels in electrolytic solutions. J. Control Release 16:319–329, 1991.CrossRefGoogle Scholar
  2. 2.
    Carr, D. A., M. Gomez-Burgaz, M. C. Boudes, and N. A. Peppas. Complexation hydrogels for the oral delivery of growth hormone and salmon calcitonin. Ind. Eng. Chem. Res. 49:11991–11995, 2010.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Darby, S. C., S. W. Kan, R. J. Spooner, P. L. F. Giangrande, F. G. H. Hill, C. R. M. Hay, C. A. Lee, C. A. Ludlam, M. Williams, and U. K. H. C. Doctors. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 110:815–825, 2007.CrossRefPubMedGoogle Scholar
  4. 4.
    Gupta, V., N. Doshi, and S. Mitragotri. Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system. PLoS One 8:e57136, 2013.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hilgendorf, C., H. Spahn-Langguth, C. G. Regardh, E. Lipka, G. L. Amidon, and P. Langguth. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J. Pharm. Sci. 89:63–75, 2000.CrossRefPubMedGoogle Scholar
  6. 6.
    Ichikawa, H., and N. A. Peppas. Novel complexation hydrogels for oral peptide delivery: in vitro evaluation of their cytocompatibility and insulin-transport enhancing effects using Caco-2 cell monolayers. J. Biomed. Mater. Res. A 67A:609–617, 2003.CrossRefGoogle Scholar
  7. 7.
    Kamei, N., M. Morishita, H. Chiba, N. J. Kavimandan, N. A. Peppas, and K. Takayama. Complexation hydrogels for intestinal delivery of interferon beta and calcitonin. J. Control Release 134:98–102, 2009.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kessler, C. M., and G. Mariani. Clinical manifestations and therapy of the hemophilias. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edited by R. W. Colman, J. Hirsh, V. J. Marder, A. W. Clowes, and J. N. George. Philadelphia: Lippincott-Raven, 2006, pp. 887–904.Google Scholar
  9. 9.
    Klinger, D., and K. Landfester. Enzymatic- and light-degradable hybrid nanogels: crosslinking of polyacrylamide with acrylate-functionalized Dextrans containing photocleavable linkers. J. Polym. Sci. A Polym. Chem. 50:1062–1075, 2012.CrossRefGoogle Scholar
  10. 10.
    Knipe, J. M., F. Chen, and N. A. Peppas. Enzymatic biodegradation of hydrogels for protein delivery targeted to the small intestine. Biomacromolecules 16:962–972, 2015.CrossRefPubMedGoogle Scholar
  11. 11.
    Koetting, M. C., and N. A. Peppas. pH-Responsive poly(itaconic acid-co-N-vinylpyrrolidone) hydrogels with reduced ionic strength loading solutions offer improved oral delivery potential for high isoelectric point-exhibiting therapeutic proteins. Int. J. Pharm. 471:83–91, 2014.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kwon, K.-C., D. Verma, N. D. Singh, R. Herzog, and H. Daniell. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv. Drug Deliv. Rev. 65:782–799, 2013.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lowman, A. M., M. Morishita, M. Kajita, T. Nagai, and N. A. Peppas. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci. 88:933–937, 1999.CrossRefPubMedGoogle Scholar
  14. 14.
    Mancuso, M. E., L. Berardinelli, C. Beretta, M. Raiteri, E. Pozzoli, and E. Santagostino. Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after 7 years of follow-up. Haematologica 94:687–692, 2009.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Morishita, M., T. Goto, K. Nakamura, A. M. Lowman, K. Takayama, and N. A. Peppas. Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats. J. Control Release 110:587–594, 2006.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nakamura, K., R. J. Murray, J. I. Joseph, N. A. Peppas, M. Morishita, and A. M. Lowman. Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on insulin delivery characteristics. J. Control Release 95:589–599, 2004.CrossRefPubMedGoogle Scholar
  17. 17.
    Peppas, N. A., P. Bures, W. Leobandung, and H. Ichikawa. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50:27–46, 2000.CrossRefPubMedGoogle Scholar
  18. 18.
    Peppas N. A. and S. D. Horava. Polymers for Delivery of Factor VIII and/or Factor IX. [Patent Pending].Google Scholar
  19. 19.
    Sharpe, L. A., A. M. Daily, S. D. Horava, and N. A. Peppas. Therapeutic applications of hydrogels in oral drug delivery. Expert Opin. Drug Deliv. 11:901–915, 2014.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Verma, D., B. Moghimi, P. A. LoDuca, H. D. Singh, B. E. Hoffman, R. W. Herzog, and H. Daniell. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc. Natl. Acad. Sci. USA 107:7101–7106, 2010.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    White, 2nd, G. C., F. Rosendaal, L. M. Aledort, J. M. Lusher, C. Rothschild, and J. Ingerslev. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 85:560, 2001.Google Scholar
  22. 22.
    Wood, K. M., G. M. Stone, and N. A. Peppas. Wheat germ agglutinin functionalized complexation hydrogels for oral insulin delivery. Biomacromolecules 9:1293–1298, 2008.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wood, K. M., G. M. Stone, and N. A. Peppas. The effect of complexation hydrogels on insulin transport in intestinal epithelial cell models. Acta Biomater. 6:48–56, 2010.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Biomedical Engineering Society 2016

Authors and Affiliations

  1. 1.McKetta Department of Chemical EngineeringThe University of Texas at AustinAustinUSA
  2. 2.Institute for Biomaterials, Drug Delivery, and Regenerative MedicineThe University of Texas at AustinAustinUSA
  3. 3.Department of Biomedical EngineeringThe University of Texas at AustinAustinUSA
  4. 4.Department of Surgery and Perioperative Care, Dell Medical SchoolThe University of Texas at AustinAustinUSA
  5. 5.Division of Pharmaceutics, College of PharmacyThe University of Texas at AustinAustinUSA

Personalised recommendations